Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.

Journal of molecular cell biology - 1 Aug 2012

Puissant Alexandre, Dufies Maeva, Fenouille Nina, Ben Sahra Issam, Jacquel Arnaud, Robert Guillaume, Cluzeau Thomas, Deckert Marcel, Tichet Mélanie, Chéli Yann, Cassuto Jill-Patrice, Raynaud Sophie, Legros Laurence, Pasquet Jean-Max, Mahon François-Xavier, Luciano Frédéric, Auberger Patrick

Abstract excerpt

Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BCR-ABL. Imatinib, an inhibitor of BCR-ABL, has emerged as the leading compound to treat CML patients. Despite encouraging clinical results, resistance to imatinib represents a major drawback for therapy, as a substantial proportion of patients are refractory to this treatment. Recent publications have described the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Epithelial-Mesenchymal Transition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Integrin alphaVbeta3

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mesoderm

Share to Piperazines

Share to Pyrimidines

Source

Identifiers

PMID: 22467682
DOI: 10.1093/jmcb/mjs010

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.PMID 22467682Read ↗

Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.Semantic proximity Read ↗

Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells.Semantic proximity Read ↗

Phenotypically plastic drug-resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model.Semantic proximity Read ↗

Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.Semantic proximity Read ↗

miR-495-3p Sensitizes BCR::ABL1 Expressing Leukemic cells to Tyrosine Kinase Inhibitors by Targeting Multidrug Resistance 1 Gene including in T315I Mutated cellsSemantic proximity Read ↗

Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cellsSemantic proximity Read ↗

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signalingSemantic proximity Read ↗

Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia.Semantic proximity Read ↗

ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML TherapySemantic proximity Read ↗

Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.Semantic proximity Read ↗

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cellsSemantic proximity Read ↗

Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.